For Audiologists

You see this every week. A patient presents with declining DPOAEs or early sensorineural hearing loss. They are not yet a candidate for amplification. You counsel on noise avoidance, recommend hearing protection, and schedule follow-up in 12 months. Between the diagnosis and the point where intervention becomes necessary, there has not been much to offer.

That gap now has published data behind a potential clinical tool.

The published evidence

A retrospective observational cohort study was published in March 2026 in Global Advances in Integrative Medicine and Health.

Design: Real-world evidence study conducted within a single audiology practice. N=190 adults with audiometrically confirmed sensorineural hearing loss.

Primary outcome: Distortion product otoacoustic emissions (DPOAEs), the measure you use routinely in your own practice.

Key finding: 75.3% of daily ACEMg users (n=93) maintained or improved DPOAE scores over a two-year follow-up period, compared to 26.8% of untreated controls (n=97).

Limitations: This is a retrospective observational study, not a randomized controlled trial. The authors disclose limitations including absence of randomization, potential for healthy-user bias, and single-practice setting. These are inherent to the real-world evidence design and are fully discussed in the published paper.

Why RWE and not an RCT: ACEMg is a commercially available dietary supplement. The research team chose a real-world evidence design to measure effectiveness in actual clinical conditions rather than efficacy under artificial constraints. The data capture what happens when real patients in a real audiology practice make their own decisions about adherence over two years. Future RCTs are warranted and welcomed.

Open access: pubmed.ncbi.nlm.nih.gov/41884353/

Raw data: osf.io/9xm4j

For the complete evidence review including preclinical research, formulation details, safety and contraindications, and conflict of interest disclosure, see the For Clinicians Overview.

Patient handout

The patient handout is written in plain language. It covers:

• The published finding (75.3% vs. 26.8% DPOAE preservation over two years)
• What the study did and did not show (including that it was not an RCT)
• What ACEMg is (formulation, ingredients, mechanism)
• Safety considerations (beta-carotene smoker warning, drug interactions)
• Cost ($33.99 per four-week supply, subscription)
• Insurance and HSA/FSA information
• Links to the published paper and raw dataset
• A section for your practice name, visit date, and personalized notes

You may reproduce this handout for clinical use without modification.

Wholesale practitioner pricing

Licensed practitioners can access wholesale pricing for in-office dispensing. Professional accounts include volume pricing, patient education materials, and access to clinical support resources.

Direct consumer purchase

Patients may also purchase ACEMg directly at shop.soundbites.com. The current subscription price is $33.99 per four-week supply (two softgels daily).

Contributing to the evidence

If you are incorporating ACEMg into your hearing preservation counseling and tracking DPOAE outcomes, your clinical data is valuable. Independent outcome reporting from audiologists across different practice settings strengthens the evidence base.

We have case report templates available for audiologists who want to document and publish their own outcomes. Contact us if you are interested.

Email: clinicians@soundbites.com

Questions

For clinical questions, evidence requests, or to discuss how other audiologists are incorporating hearing preservation counseling:

Email: clinicians@soundbites.com

These statements have not been evaluated by the Food and Drug Administration. ACEMg is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease.